1070nm Intranasal Stimulation Pilot Trial Device
There is a growing body of evidence supporting the use of 1070nm near-infrared light photobiomodulation (PBM) to prevent COVID infection, reduce its virulence and mitigate post-infection neurological injury. This unit is being developed specifically to deliver 200mw of 1070nm infrared light directly into the nose to support the immune system's response to COVID 19.
This MedCram video presents a recently published clinical trial showing that direct PBM stimulation to the chest produced highly significant improvement in subjects with COVID 19 symptoms. This pilot project will utilize many of the same dependent measures and endpoints and using the intranasal delivery system instead of the vest.
Given the primary entry point for COVID is through the nose, this would then be the most useful location for mitigation. Killing the virus at this point may reduce infectivity and symptom severity. We know the entire body's blood supply passes through our face every 4 minutes. PBM stimulation through the nasal cavity would irradiate all free-floating mitochondria in the blood and then be available throughout the body including the brain.
Users of this device will be enrolled as subjects in an ongoing open-label aggregated case series protocol and will be required to monitor and share specific health information including heart and respiration rates during and after using the device. This project will be conducted under the auspices of the Quietmind Foundation (QMF) and monitored by the QMF Institutional Review Board.
Informed consent documents and related enrollment materials will be provided once IRB approval has been obtained.
Only clinicians seeking to serve as prospective research sites are welcome to obtain devices at this time but they are not to use it with patients. Their use now is only to familiarize themselves with the device's operation, assist in study logistics design, and their own personal experience.